Vernalis Research | Fragment & Structure-Based Drug Discovery

Popular pages

• About us

  Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects

• News & Publications

  Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary... <a class="read-more-link" href="https://w...

• Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a

  Cambridge UK, and Copenhagen, Denmark, 14 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma... <a class="read-more-link" href="https://www.ve...

• Vernalis, a fully owned subsidiary of HitGen Inc., and Servier achieve two milestones in their

  Chengdu, China, 10 June 2021 – Vernalis, a fully owned subsidiary of HitGen Inc., and Servier are pleased to announce... <a class="read-more-link" href="https://www.vernalis.com/vernalis-and-servier-a...

• Vernalis licenses proprietary adenosine receptor antagonist technology, including lead compound

  Vernalis plc today announces that it has licensed exclusive, worldwide rights in its adenosine receptor antagonist programme, including the lead drug candidate, V81444, for use in all therapeutic appl...